Wall Street Zen Downgrades Lumexa Imaging (NASDAQ:LMRI) to Hold

Key Points

• Wall Street Zen downgraded Lumexa Imaging to “Hold” from “Buy,” although the broader analyst consensus remains “Moderate Buy” with a $17.33 price target.
• Lumexa Imaging shares opened at $11.49, near their 50-day average of $11.53, with a market capitalization of approximately $1.10 billion and a 52-week range of $6.45 to $19.45.
• The company reported quarterly earnings of $0.20 per share, beating estimates of $0.03, and issued fiscal 2026 EPS guidance of $0.71 to $0.77; several major institutional investors also recently initiated positions.

Lumexa Imaging (NASDAQ:LMRI - Get Free Report) was downgraded by analysts at Wall Street Zen from a "buy" rating to a "hold" rating in a note issued to investors on Saturday, Wall Street Zen reports.

Several other brokerages also recently issued reports on LMRI. Deutsche Bank Aktiengesellschaft set a $16.00 price target on Lumexa Imaging in a research report on Thursday, August 13th. Barclays boosted their price target on Lumexa Imaging from $9.00 to $13.00 and gave the company an "overweight" rating in a research note on Friday, August 28th. Finally, Weiss Ratings raised Lumexa Imaging from a "sell (e)" rating to a "sell (d)" rating in a report on Thursday, June 25th. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, Lumexa Imaging currently has a consensus rating of "Moderate Buy" and a consensus price target of $17.33.

Lumexa Imaging Stock Performance

NASDAQ:LMRI opened at $11.49 on Friday. The company has a current ratio of 1.44, a quick ratio of 1.44 and a debt-to-equity ratio of 1.40. Lumexa Imaging has a twelve month low of $6.45 and a twelve month high of $19.45. The firm has a market cap of $1.10 billion and a price-to-earnings ratio of -23.45. The company has a 50-day moving average of $11.53 and a 200-day moving average of $10.70.

Lumexa Imaging (NASDAQ:LMRI - Get Free Report) last released its earnings results on Wednesday, August 12th. The company reported $0.20 earnings per share for the quarter, topping the consensus estimate of $0.03 by $0.17. The firm had revenue of $264.16 million during the quarter. Lumexa Imaging has set its FY 2026 guidance at 0.710-0.770 EPS. Analysts forecast that Lumexa Imaging will post 0.25 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Lumexa Imaging

Hedge funds and other institutional investors have recently made changes to their positions in the business. Geode Capital Management LLC bought a new stake in Lumexa Imaging in the fourth quarter valued at about $1,548,000. Seven Grand Managers LLC acquired a new stake in Lumexa Imaging during the fourth quarter valued at approximately $11,942,000. Goldman Sachs Group Inc. acquired a new stake in Lumexa Imaging during the fourth quarter valued at approximately $18,870,000. TD Asset Management Inc bought a new stake in shares of Lumexa Imaging in the 4th quarter valued at approximately $1,264,000. Finally, JPMorgan Chase & Co. acquired a new position in shares of Lumexa Imaging in the 4th quarter worth approximately $15,954,000.

Lumexa Imaging Company Profile

We are one of the largest national providers of diagnostic imaging services(1). Our platform is integrated, scalable and has a proven track record of creating value for our stakeholders. As of September 30, 2025, we and our affiliates operated the second largest(1) outpatient imaging center footprint in the United States. It spans 184 centers(2)across 13 states and includes eight joint venture partnerships with health systems. Our centers are in attractive metropolitan statistical areas (“MSAs”).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.